KLAR Klaria Pharma Holding AB (publ.)
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Klaria Pharma Holding (STO: KLAR)
›
Klaria Pharma Holding (STO: KLAR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.5190 SEK on 19 November 2026, up 8.6% over 52 weeks. Its 52-week range is 0.4500 SEK to 1.330 SEK: the price is 61.0% below the high and 15.3% above the low.
Its market capitalisation is 127.66M SEK.
Klaria Pharma Holding reports return on equity of 390.7%.
It holds more cash than debt, a net cash position of 8.47M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.